Apexigen has filed a notice of an exempt offering of securities to raise $5,587,982.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Apexigen is raising $5,587,982.00 in new funding. Sources indicate as part of senior management Chief Operating Officer, Francis Sarena played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Apexigen
Apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative immuno-oncology therapeutics generated by APXiMAB, the Companys proprietary antibody drug discovery platform. Its lead immuno-oncology drug candidate, APX005M, is a potent immune-activating antibody against CD40 currently in Phase 2 clinical development.
To learn more about Apexigen, visit http://www.apexigen.com/
Contact:
Francis Sarena, Chief Operating Officer
650-931-6236
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.